Helen of Troy (HELE) Tops Q2 EPS by 12c
More News related to HELE
- RBC Initiates Coverage on Helen of Troy (HELE) with a Sector Perform
- Morning Movers 10/07: RPRX, DDSS, GTA, CHIP, UCBH, BSMD Higher; MERX, AAI, APPY, SGMO, SIRI Lower
- Helen of Troy (HELE) Tops Q2 EPS by 12c
- Helen of Troy Limited Reports Increased Second Quarter Net Earnings and Record Sales for the Quarter and Year-to-Date
- Trading Radar for 10/07: Alcoa (AA), Monsanto (MON), Costco (COST), Family Dollar (FDO), Wolverine World Wide (WWW), Ruby Tuesday (RT) Report; Crude Inventories, Consumer Credit, Budget Due
More News related to Earnings
- After-Hours Movers 11/24: QADI, JCG, ASYS Higher; DRAM, CWTR Lower
- Trading Radar for 11/25: Deere & Co. (DE), Tiffany & Co. (TIF), Conn's (CONN) Report
- Afternoon ETF Check: SMH Up; XLF, TAN, EWJ Down
- Unusual 11 Mid-Day Movers 11/24: IWA, DRAM, ABG, TIXC Higher; WH, WMG, ABIO, NYNY Lower
- Notable Analyst Rating Changes 11/24: ABG, PRU, RS, AYI, AMLN, TLAB Upgraded; DELL, CIEN, UNP, ALV Downgraded
Helen of Troy Limited (Nasdaq: HELE) reports Q2 EPS of $0.51, above the consensus of $0.39. Revenues rose 5.6% to $162.2 million, versus the consensus of $159.2 million.
The CEO stated, "We are extremely pleased with our results for the second quarter. Although the worldwide retail environment continues to be challenging, our leadership position in our market segments allowed us to continue to perform well during the quarter. During the six months ended August 31, 2009 our Housewares division continued to expand our OXO brand with the completion of two strategic licensing agreements with Staples Inc., the world's largest office products company, and UCB, a global biopharmaceutical leader. These two partnerships extend OXO's reach into new and exciting categories... We believe our Company's core strengths remain strong, and we continue to work on the five Company initiatives detailed in our 2009 annual report."
Related Categories
EarningsHot List
Stocks Mentioned
-0.24Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
